References of "KRZESINSKI, Jean-Marie"
     in
Bookmark and Share    
Full Text
See detailL'hypertension artérielle
Krzesinski, Jean-Marie ULg

Conference (2014, May 08)

Detailed reference viewed: 58 (0 ULg)
Full Text
Peer Reviewed
See detailCinacalcet treatment at the time of transplantation is associated with a significant risk of delayed graft function in kidney transplant recipients
Jouret, François ULg; WEEKERS, Laurent ULg; GROSCH, Stéphanie ULg et al

in Transplant International (2014, May), 27(S1), 167

The calcium-sensing receptor (CaSR) has been implicated in the ischemia/ reperfusion (I/R) cascade in heart, liver and brain. Renal I/R occurs at the time of transplantation (Tx), with a deleterious ... [more ▼]

The calcium-sensing receptor (CaSR) has been implicated in the ischemia/ reperfusion (I/R) cascade in heart, liver and brain. Renal I/R occurs at the time of transplantation (Tx), with a deleterious impact on early graft function. Here, we retrospectively investigated if the use of cinacalcet, a CaSR agonist, in kidney transplant recipients (KTR) influences early graft recovery. All KTR from 2007 to 2012 in our Academic Hospital were prospectively included in a database. Patients actively treated with cinacalcet on the day of Tx were retrospectively identified from this database and matched with controls on (i) type of donor (living [LD], deceased after brain or circulatory death [DCD]); (ii) cold ischemic time (CIT) ` 1 h; (iii) residual diuresis (` 500 ml); and (iv) donor age (` 5 years). Delayed graft function (DGF) was defined as dialysis requirement after Tx. Baseline characteristics were compared between groups with student’s t-test or Chi-2 as appropriate. The endpoint was the percentage of DGF in both groups. Among 337 KTR, 36 (10.7%) were treated with cinacalcet at Tx. Control group included 61 patients. Characteristics of patients and donors are summarized in the table. DGF occurred in 42 and 23% of cinacalcet-treated and control groups, respectively (p = 0.05). These retro- spective observations suggest that CaSR activation at the time of Tx impairs early graft recovery. [less ▲]

Detailed reference viewed: 56 (13 ULg)
Full Text
See detailComportements à risque et maladies cardio-vasculaires. Comment infléchir le cours des choses?
Etienne, Anne-Marie ULg; Krzesinski, Jean-Marie ULg; André, Jean-François

Scientific conference (2014, April 01)

«Comportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses ?» Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients ... [more ▼]

«Comportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses ?» Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients, comment améliorer la prévention dans le domaine cardio-vasculaire ? [less ▲]

Detailed reference viewed: 32 (16 ULg)
Full Text
See detailComportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses?
Krzesinski, Jean-Marie ULg; andre, Jean-François

Conference (2014, April 01)

Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients, comment améliorer la prévention dans le domaine cardio-vasculaire?

Detailed reference viewed: 15 (6 ULg)
Full Text
See detailTraitement antihypertenseur : quelles sont les meilleures associations?
Krzesinski, Jean-Marie ULg

Conference (2014, February 22)

Stratégie du traitement de l’HTA en 2014: toujours basée sur le calcul du risque CV. L’HTA, tueur silencieux, est généralement associée à de nombreux autres facteurs de risque CV. Il faut préciser le ... [more ▼]

Stratégie du traitement de l’HTA en 2014: toujours basée sur le calcul du risque CV. L’HTA, tueur silencieux, est généralement associée à de nombreux autres facteurs de risque CV. Il faut préciser le niveau de risque CV en tenant compte de la valeur de PA et des autres F.R. pour décider le moment et le type de traitement ! [less ▲]

Detailed reference viewed: 27 (1 ULg)
Peer Reviewed
See detailUn cas particulier d'amyloïdose AA
MILICEVIC, Martina ULg; GROSCH, Stéphanie ULg; Krzesinski, Jean-Marie ULg et al

Conference (2014, January 22)

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailDetection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Morel, Jérôme et al

in BMC Nephrology (2014), 15(9), 1471-2369

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailEstimation du débit de filtration glomérulaire en 2014
DELANAYE, Pierre ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2014), 69

Chronic kidney disease (CKD) is a frequent affection, most often detected by evaluation of the glomerular filtration rate (GFR). Measuring GFR by a reference method is not possible for every single ... [more ▼]

Chronic kidney disease (CKD) is a frequent affection, most often detected by evaluation of the glomerular filtration rate (GFR). Measuring GFR by a reference method is not possible for every single patient, even if these methods are probably underused. However, serum creatinine has several limitations of which clinicians should be aware. Knowing these limitations, creatinine and creatinine-based équations (including other parameters like age, gender and ethnicity) still represent the most used and easiest way to detect and assess CKD. [less ▲]

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailMesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion.
Erpicum, Pauline; Detry, Olivier; Weekers, Laurent et al

in Nephrology Dialysis Transplantation (2014), 29

Acute kidney injury (AKI) represents a worldwide public health issue of increasing incidence, with a significant morbi-mortality. AKI treatment mostly relies on supportive manoeuvres in the absence of ... [more ▼]

Acute kidney injury (AKI) represents a worldwide public health issue of increasing incidence, with a significant morbi-mortality. AKI treatment mostly relies on supportive manoeuvres in the absence of specific target-oriented therapy. The pathophysiology of AKI commonly involves ischaemia/reperfusion (I/R) events, which cause both immune and metabolic consequences in renal tissue. Similarly, at the time of kidney transplantation (KT), I/R is an unavoidable event which contributes to early graft dysfunction and enhanced graft immunogenicity. Mesenchymal stromal cells (MSCs) represent a heterogeneous population of adult, fibroblast-like multi-potent cells characterized by their ability to differentiate into tissues of mesodermal lineages. Because MSC have demonstrated immunomodulatory, anti-inflammatory and tissue repair properties, MSC administration at the time of I/R and/or at later times has been hypothesized to attenuate AKI severity and to accelerate the regeneration process. Furthermore, MSC in KT could help prevent both I/R injury and acute rejection, thereby increasing graft function and survival. In this review, summarizing the encouraging observations in animal models and in pilot clinical trials, we outline the benefit of MSC therapy in AKI and KT, and envisage their putative role in renal ischaemic conditioning. [less ▲]

Detailed reference viewed: 37 (17 ULg)
Full Text
Peer Reviewed
See detailScreening, early diagnosis, genetic markers, and predictors of diabetic nephropathy
Cohen, Eric P.; Krzesinski, Jean-Marie ULg

in Lerna, Edgar V.; Batuman, Vecihi (Eds.) Diabetes and kidney disease (2014)

Kidney disease in diabetes greatly diminishes quality and quantity of life, and is very expensive. Focused attention to the early stages of diabetic nephropathy is urgently needed, to define better ... [more ▼]

Kidney disease in diabetes greatly diminishes quality and quantity of life, and is very expensive. Focused attention to the early stages of diabetic nephropathy is urgently needed, to define better thérapies that may slow it down or even stop its progression, thus reducing its heavy burden. This chapter will address screening, early diagnosis, genetic markers, and predictors of diabetic nephropathy. [less ▲]

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailTwo novel mutations of the CLDN16 gene cause familial hypomagnesaemia with hypercalciuria and nephrocalcinosis
Hanssen, Oriane ULg; CASTERMANS, Emilie ULg; BOVY, Christophe ULg et al

in Clinical Kidney Journal (2014), 7

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis is an autosomal-recessive disease caused by mutations in the CLDN16 or CLDN19 genes, which encode tight junction-associated proteins ... [more ▼]

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis is an autosomal-recessive disease caused by mutations in the CLDN16 or CLDN19 genes, which encode tight junction-associated proteins, claudin-16 and -19. The resultant tubulopathy leads to urinary loss of Mg2+ and Ca2+, with subsequent nephrocalcinosis and end-stage renal disease (ESRD). An 18-year-old boy presented with chronic kidney disease and proteinuria, as well as hypomagnesaemia, hypercalciuria and nephrocalcinosis. A kidney biopsy revealed tubular atrophy, interstitial fibrosis and segmental sclerosis of some glomeruli. Two novel mutations in the CLDN16 gene were identified: c.340C>T (nonsense) and c.427+5G>A (splice site). The patient reached ESRD at 23 and benefited from kidney transplantation. [less ▲]

Detailed reference viewed: 16 (11 ULg)
Full Text
See detailPrise en charge de l'hypertension. Nouvelles recommandations et objectifs à atteindre chez le diabétique (DT).
Krzesinski, Jean-Marie ULg

Scientific conference (2013, November 16)

La prise en charge de l’HTA chez le DT est importante car cette double pathologie expose à un risque majeur cardiovasculaire et rénal. L’approche doit être multifactorielle et globale. Pour l’HTA, la ... [more ▼]

La prise en charge de l’HTA chez le DT est importante car cette double pathologie expose à un risque majeur cardiovasculaire et rénal. L’approche doit être multifactorielle et globale. Pour l’HTA, la cible préconisée est actuellement de 140/85 mmHg mais on peut imaginer qu’un patient sans comorbidité puisse atteindre une cible plus basse. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailModification of diet in renal disease versus chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in obese patients
BOUQUEGNEAU, Antoine ULg; Vidal-Petiot, Emanuelle; Vrtovsnik, François et al

in Nephrology Dialysis Transplantation (2013), 28(4), 122-130

Background Obesity is a recognized risk factor for both the development and progression of chronic kidney disease (CKD). Accurate estimation of glomerular filtration rate (GFR) is thus important in these ... [more ▼]

Background Obesity is a recognized risk factor for both the development and progression of chronic kidney disease (CKD). Accurate estimation of glomerular filtration rate (GFR) is thus important in these patients. We tested the performances of two creatinine-based GFR estimates, the Modification of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations, in an obese population. Methods Patients with body mass index (BMI) > 30 kg/m2 were included. The reference method for measured GFR (mGFR) was 51Cr-EDTA (single-injection method, two blood samples at 120 and 240 min). Both indexed and non-indexed results were considered. Serum creatinine was measured using the IDMS-traceable compensated Jaffe method. Mean bias (eGFR–mGFR), precision (SD around the bias) and accuracy within 30% (percentage of estimations within 30% of mGFR) were calculated for both equations. Results The population included 366 patients (185 women) from two different areas. Mean age was 55 ± 14 years, and mean BMI was 36 ± 7 kg/m2. Mean mGFR was 56 ± 26 mL/min/1.73 m2 (71 ± 35 mL/min without indexation). In the total population, mean bias was +1.9 ± 14.3 and +4.6 ± 14.7 mL/min/1.73 m2 (P < 0.05), and accuracy 30% was 80 and 76% for the MDRD and CKD-EPI equations (P < 0.05), respectively. In patients with mGFR > 60 mL/min/1.73 m2, mean bias was +4.6 ± 18.4 and +9.3 ± 17.2 mL/min/1.73 m2 (P < 0.05), and accuracy 30% was 81 and 79% (NS) for the MDRD and CKD-EPI equations, respectively. Conclusions The CKD-EPI equation did not outperform the MDRD study equation in this population of obese patients [less ▲]

Detailed reference viewed: 34 (12 ULg)
Full Text
Peer Reviewed
See detailBlood pressure dipping and arterial stiffness in kidney transplant recipients
XHIGNESSE, Patricia ULg; Saint-Remy, Annie ULg; BONVOISIN, Catherine ULg et al

Conference (2013, October 05)

In 70 kidney transplant recipients, nocturnal blood pressure(BP) nondipping (nondipping or reversed rhythm) was highly frequent (48% were nondippers and 29% had a reversed rhythm). When compared dippers ... [more ▼]

In 70 kidney transplant recipients, nocturnal blood pressure(BP) nondipping (nondipping or reversed rhythm) was highly frequent (48% were nondippers and 29% had a reversed rhythm). When compared dippers, nondippers and reversed, neither BMI, time on hemodialysis, graft survival, eGFR or antihypertensive drugs allowed to distinct the three groups. Pulse Wave Velocity (PWV) did not differ between groups but calcification score and ambulatory arterial stiffness index (AASI) were significantly the highest in récipients with reversed rhythm. That was also the case in nondippers recipients. [less ▲]

Detailed reference viewed: 40 (3 ULg)
Full Text
See detailComment concilier médecine factuelle et médecine personnalisée en pratique clinique
Krzesinski, Jean-Marie ULg

Conference (2013, October 01)

Médecine factuelle (EBM) et médecine personnalisée : définition, avantages et limites. Cas cliniques exemplatifs dans l'HTA

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detail« Quoi de neuf pour la prise en charge de l’hypertension artérielle en 2013 ? » Nouvelles directives des Sociétés Européennes d’Hypertension et de Cardiologie.
XHIGNESSE, Patricia ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2013), 68(10), 511-520

The 2013 guidelines for arterial hypertension have just been released by the European Societies of Cardiology and Hypertension. As already discussed in earlier versions, the decision to treat must be ... [more ▼]

The 2013 guidelines for arterial hypertension have just been released by the European Societies of Cardiology and Hypertension. As already discussed in earlier versions, the decision to treat must be based on the assessment of the cardiovascular risk. The value of out-of-the office blood pressure measurements to confirm the diagnosis of hypertension is underlined and the authors stress the need for a close follow up of non pharmacological therapeutic measures. A novelty, however, consists in the simplification of the blood pressure target under treatment, which must be < 140/90 mmHg in the vast majority of patients, except for octogenerians whose systolic blood pressure target should be < 150 mmHg. For resistant hypertension, renal denervation and carotid baroreceptor stimulation are proposed as new invasive modes of therapy; their clinical values, however, remain to be confirmed. [less ▲]

Detailed reference viewed: 85 (5 ULg)
Full Text
See detailCardiac surgery and acute kidney injury.
LAGNY, Marc-Gilbert ULg; BLAFFART, Francine ULg; KOCH, Jean-Noël ULg et al

Conference given outside the academic context (2013)

Lecture about Cardiac surgery and acute kidney injury. Presentations of results about a retrospective study performed in the University Hospital of Liège and presentations about the protocol of a ... [more ▼]

Lecture about Cardiac surgery and acute kidney injury. Presentations of results about a retrospective study performed in the University Hospital of Liège and presentations about the protocol of a prospective study on the same topic. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailCholecaciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study
DELANAYE, Pierre ULg; WEEKERS, Laurent ULg; WARLING, Xavier et al

in Nephrology Dialysis Transplantation (2013), 28(7), 1779-1786

Background. The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether ... [more ▼]

Background. The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether cholecalciferol therapy can increase serum 25-hydroxyvitamin D [25(OH)D] levels in haemodialysed patients and the safety implications of this therapy on certain biological parameters and vascular calcifications score. Methods. Forty-three haemodialysis patients were randomized to receive placebo or cholecalciferol (25 000 IU) therapy every 2 weeks. The biological parameters, serum calcium, phosphorus, 25(OH)D and parathormone (PTH) levels, were monitored monthly for 12 consecutive months. Vascular calcifications were assessed by lateral X-ray radiography. Results. At baseline, the mean serum 25(OH)D levels were low and similar in both groups. Thirty patients (16 treated and 14 placebo) completed the study: 11 patients died (5 placebo and 6 treated), 1 patient dropped out and 1 patient was transplanted (both from the placebo group). After 1 year, the percentage of 25(OH)D deficient patients was significantly lower in the treated group. None of the patients developed hypercalcaemia. The PTH levels tended to increase over the study period under placebo and to decrease in the cholecalciferol group. The median changes in PTH levels from baseline to 1 year were statistically different between the two groups [+80 (−58 to 153) and −115 (−192 to 81) under placebo and cholecalciferol treatment, respectively, P = 0.02].The calcification scores increased equivalently in both groups (+2.3 per year). Conclusions. Cholecalciferol is effective and safe, and does not negatively affect calcium, phosphorus, PTH levels and vascular calcifications. Additional studies are needed to compare the impacts of nutritional and active vitamin D agents on vascular calcification and mortality. [less ▲]

Detailed reference viewed: 33 (10 ULg)